The Team

The Novelix leadership team has track records in all of the areas needed for the successful bench-to-bedside development of targeted cancer therapeutics: identification and validation of high-value targets, preclinical and clinical drug development, trial design, biostatistics, clinical oncology, business development, corporate law, intellectual property law and finance. Team members have worked closely with each other on related ventures over the last 15 years and are intimately familiar with the company’s compounds, technologies and platforms. All team members have previously consulted for, worked in, or founded biotechnology or biopharmaceutical companies. Recently, the company added a general counsel and a senior IP lawyer to its team. Novelix has also established a high-profile Scientific Advisory Board (SAB, please click for details) to help guide its aggressive development program.

Burkhard Jansen, M.D. – Director, President, CEO & Founder
Dr. Jansen is internationally recognized for his expertise in the development of targeted cancer therapeutics, with over 15 years of experience. Prior to co-founding Novelix, he was VP, Clinical Development, at Oncogenex, where he brought the company’s first lead compound into clinical trials and built a product pipeline in less than 2 years. Previously, he worked at the FDA and was the Head of Experimental Oncology and Molecular Pharmacology at the University of Vienna in Austria. Dr. Jansen, played a leading role in the highly successful phase I-II development of Genasense^TM, which was the subject of one of the most notable transactions in the history of biotech, exceeding $ 400 million.
Tim Triche, M.D., Ph.D. – Chairman & Founder
Dr. Triche is a seasoned executive who also has over 25 years of experience in cancer diagnosis and patient treatment. He is currently the Chief Pathologist at the Childrens Hospital Los Angeles and Vice Chairman of the Department of Pathology, USC School of Medicine. He has served as senior executive, director, or scientific advisor to a number of medical companies, including Chairman and CEO of Oncormed, and is a recognized expert in the analysis and use of cancer targets and pathways. He has raised more than $70 million in public markets for publicly held companies.
Jeremy Teraoka, F.C.A. (UK) – Director, Chief Financial Officer & Founder
Mr. Teraoka has 25 years of experience with international companies. He co–founded Asia Equity, a stock brokerage which grew over a nine year period to 700 employees. Asia Equity was sold to Banque Paribas in 1998 for $100 million. Most recently, he was a Director and CFO of MDX Medical, a publicly listed medical technology company in Canada. Previously, Mr. Teraoka served as the Head of Operations - Equities for Banque Paribas, Asia Equity; Group Finance Director and Member of the Executive Committee for the Asia Equity Group; Far East Controller for Swiss Bank Corporation; and qualified with Peat Marwick in London.
Richard Southard, J.D. – General Counsel
Mr. Southard brings a diversity of legal and operating experiences with him. He joined Telcom Ventures, a private equity firm specializing in new and emerging telecommunications and information technologies in the U.S., Latin America, Europe and India. His role evolved into operations, including two years as the managing director of a technology company in Venezuela. Upon returning to the USA, Rich helped HNC Software, Inc. to launch its solutions division. He most recently led the San Diego division of Motivational Systems, Inc. as Vice-President and Division Manager.
Jonathan Buckley, M.D., Ph.D. – VP, Clinical Development & Founder
Dr. Buckley has over 25 years experience in clinical trial design and biostatistics and is a Professor at the Keck School of Medicine and the Norris Cancer Center at USC. He has coordinated clinical trials for an international cancer network, and also developed Genetrix, a proprietary bioinformatics analysis system capable of identifying patient populations likely to benefit from a given targeted therapeutic. Dr. Buckley is not only a clinical development expert, he is an experienced business executive who founded and led Epicenter Software since 1984. Epicenter develops and markets software for the management and analysis of genetic data for drug development and patient selection.
Poul Sorensen, M.D., Ph.D. – Founder & Chief Science Consultant
Dr. Sorensen has over 15 years experience in tumor biology and cancer drug target identification. He is Director of the Tumor Genetics Laboratory and a Professor of Pathology at the University of British Columbia (UBC), and a Senior Scientist at the British Columbia Cancer Research Centre in Vancouver, Canada. Dr. Sorensen is the Chair of the Translational Research Committee of the Children’s Oncology Group, one of the world’s largest oncology networks. He is also an internationally recognized Molecular Pathologist, an expert in genetic alterations that occur in cancer and an expert in the evaluation and optimization of novel agents that influence these alterations.

The Team The Novelix leadership team has track records in all of the areas needed for the successful bench-to-bedside development of targeted cancer therapeutics: identification and validation of high-value targets, preclinical and clinical drug development, trial design, biostatistics, clinical oncology, business development, corporate law, intellectual property law and finance. Team members have worked closely with each other on related ventures over the last 15 years and are intimately familiar with the company’s compounds, technologies and platforms. All team members have previously consulted for, worked in, or founded biotechnology or biopharmaceutical companies. Recently, the company added a general counsel and a senior IP lawyer to its team. Novelix has also established a high-profile Scientific Advisory Board (SAB, please click for details) to help guide its aggressive development program. Burkhard Jansen, M.D. – Director, President, CEO & Founder Dr. Jansen is internationally recognized for his expertise in the development of targeted cancer therapeutics, with over 15 years of experience. Prior to co-founding Novelix, he was VP, Clinical Development, at Oncogenex, where he brought the company’s first lead compound into clinical trials and built a product pipeline in less than 2 years. Previously, he worked at the FDA and was the Head of Experimental Oncology and Molecular Pharmacology at the University of Vienna in Austria. Dr. Jansen, played a leading role in the highly successful phase I-II development of Genasense^TM, which was the subject of one of the most notable transactions in the history of biotech, exceeding $ 400 million. Tim Triche, M.D., Ph.D. – Chairman & Founder Dr. Triche is a seasoned executive who also has over 25 years of experience in cancer diagnosis and patient treatment. He is currently the Chief Pathologist at the Childrens Hospital Los Angeles and Vice Chairman of the Department of Pathology, USC School of Medicine. He has served as senior executive, director, or scientific advisor to a number of medical companies, including Chairman and CEO of Oncormed, and is a recognized expert in the analysis and use of cancer targets and pathways. He has raised more than $70 million in public markets for publicly held companies. Jeremy Teraoka, F.C.A. (UK) – Director, Chief Financial Officer & Founder Mr. Teraoka has 25 years of experience with international companies. He co–founded Asia Equity, a stock brokerage which grew over a nine year period to 700 employees. Asia Equity was sold to Banque Paribas in 1998 for $100 million. Most recently, he was a Director and CFO of MDX Medical, a publicly listed medical technology company in Canada. Previously, Mr. Teraoka served as the Head of Operations - Equities for Banque Paribas, Asia Equity; Group Finance Director and Member of the Executive Committee for the Asia Equity Group; Far East Controller for Swiss Bank Corporation; and qualified with Peat Marwick in London. Richard Southard, J.D. – General Counsel Mr. Southard brings a diversity of legal and operating experiences with him. He joined Telcom Ventures, a private equity firm specializing in new and emerging telecommunications and information technologies in the U.S., Latin America, Europe and India. His role evolved into operations, including two years as the managing director of a technology company in Venezuela. Upon returning to the USA, Rich helped HNC Software, Inc. to launch its solutions division. He most recently led the San Diego division of Motivational Systems, Inc. as Vice-President and Division Manager. Jonathan Buckley, M.D., Ph.D. – VP, Clinical Development & Founder Dr. Buckley has over 25 years experience in clinical trial design and biostatistics and is a Professor at the Keck School of Medicine and the Norris Cancer Center at USC. He has coordinated clinical trials for an international cancer network, and also developed Genetrix, a proprietary bioinformatics analysis system capable of identifying patient populations likely to benefit from a given targeted therapeutic. Dr. Buckley is not only a clinical development expert, he is an experienced business executive who founded and led Epicenter Software since 1984. Epicenter develops and markets software for the management and analysis of genetic data for drug development and patient selection. Poul Sorensen, M.D., Ph.D. – Founder & Chief Science Consultant Dr. Sorensen has over 15 years experience in tumor biology and cancer drug target identification. He is Director of the Tumor Genetics Laboratory and a Professor of Pathology at the University of British Columbia (UBC), and a Senior Scientist at the British Columbia Cancer Research Centre in Vancouver, Canada. Dr. Sorensen is the Chair of the Translational Research Committee of the Children’s Oncology Group, one of the world’s largest oncology networks. He is also an internationally recognized Molecular Pathologist, an expert in genetic alterations that occur in cancer and an expert in the evaluation and optimization of novel agents that influence these alterations.
Home
User login Username: Password: Create new account Request new password

The Team

User login